• positroscint@gmail.com
  • 0176-2206156
  • 0172-2652700
  • 99888-83007
Get A Quote
  • positroscint@gmail.com
  • 0176-2206156
  • 0172-2652700
  • 99888-83007
Get A Quote

18F] Fluorine-labeled Prostate-Specific Membrane Antigen (F-PSMA)

OVERVIEW

[^18F] Fluorine-labeled Prostate-Specific Membrane Antigen (F-PSMA) is a radiopharmaceutical used in positron emission tomography (PET) imaging for prostate cancer. It targets the prostate-specific membrane antigen (PSMA), a transmembrane protein highly expressed in prostate cancer cells, making it an effective marker for prostate cancer detection, staging, and monitoring.

Mechanism of Action

F-PSMA is a small molecule inhibitor that selectively binds to PSMA receptors on the surface of prostate cancer cells. Once administered, it rapidly accumulates in prostate cancer tissues due to its high affinity for PSMA. The fluorine-18 radionuclide emits positrons that can be detected by PET scanners, allowing for the visualization and quantification of PSMA expression levels in the prostate and metastatic lesions.

Applications in Prostate Cancer Imaging

F-PSMA PET imaging has several clinical applications in the management of prostate cancer:

Diagnosis and Staging

  • Primary Tumor Detection: F-PSMA PET helps localize the primary prostate tumor and differentiate it from benign prostatic hyperplasia.
  • Lymph Node Involvement: It accurately detects lymph node metastases, aiding in staging and treatment planning.
  • Bone Metastases: F-PSMA PET is highly sensitive for detecting bone metastases, which are common in advanced prostate cancer.

Monitoring Therapeutic Response and Recurrence Detection

  • Assessment of Treatment Response: F-PSMA PET can evaluate the response to therapy by monitoring changes in PSMA expression and tumor metabolic activity.
  • Detection of Recurrence: It is highly sensitive for detecting disease recurrence, even at low prostate-specific antigen (PSA) levels, allowing for early intervention.

Treatment Planning

  • Radiation Therapy: F-PSMA PET assists in delineating tumor boundaries and identifying areas of residual disease after prostatectomy, guiding the delivery of targeted radiation therapy.
  • Surgery: It helps surgeons identify the extent of disease and plan surgical resections more accurately.

Advantages

F-PSMA PET imaging offers several advantages over conventional imaging modalities such as CT and bone scintigraphy:

  • High Sensitivity and Specificity: F-PSMA PET has demonstrated superior sensitivity and specificity for detecting prostate cancer lesions, including small metastatic deposits.
  • Whole-Body Imaging: It provides comprehensive whole-body imaging, allowing for the detection of both local and distant metastases in a single scan.
  • Early Detection: F-PSMA PET can detect recurrent disease at lower PSA levels compared to conventional imaging techniques, enabling earlier intervention and potentially improving patient outcomes.
  • Quantitative Analysis: PET imaging allows for quantitative analysis of PSMA expression levels, which may aid in treatment response assessment and prognostication.

Contact Info

  • Plot No. 907, Industrial Area ||, Chandigarh - 160002
  • Plot No. 15, Village Bhagwanpur, Tehsil - 140507 Derabassi, Dist. SAS Nagar
  • 0176-2206156, 0172-2652700, 99888-83007
  • positroscint@gmail.com

Social Icon

Quick Links

Newsletter

    Copyright@2023-24 Reserved By PositroScint Pvt. Ltd.

    Powered By NET Xperia | Call Us : +91-7210449958